Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Aug 14, 2015; 21(30): 9163-9174
Published online Aug 14, 2015. doi: 10.3748/wjg.v21.i30.9163
Table 3 Analyses of factors related to sustained virologic response: Univariate and multivariate effectiveness analysis
ITT
mITT
Univariate
Multivariate
Univariate
Multivariate
OR95%CIP valueOR95%CIP valueOR95%CIP valueOR95%CIP value
Previous response1
R2.61.8-3.70.0001.81.09-3.10.0222.41.6-3.50.0001.91.1-3.30.019
PR0.90.6-1.3NS0.90.5-1.7NS0.90.6-1.3NS0.80.4-1.6NS
NR0.40.2-0.50.0000.60.37-0.90.3300.50.3-0.70.0000.70.39-1.1NS
IL28B2
CC3.62.2-5.90.0003.071.5-5.90.0013.21.9-5.40.0003.01.4-6.00.002
CT1.81.2-2.60.0031.61.001-2.60.0491.81.2-2.80.0041.60.9-2.7NS
Fibrosis3
Non-F42.11.6-2.80.0002.01.33-3.00.0012.261.7-3.040.0002.11.4-3.30.000
Treatment4
TVR1.71.3-2.10.0001.51.02-2.20.0381.10.9-1.5NS1.10.7-1.7NS
LogGGT0.190.12-0.30.0000.30.18-0.600.20.15-0.230.0000.40.2-0.70.004
LogViral load0.80.6-1.003NS0.70.5-0.990.0480.80.6-1.003NS0.70.4-1.1NS

  • Citation: Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174
  • URL: https://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v21.i30.9163